Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “buy” rating reaffirmed by investment analysts at Cantor Fitzgerald in a note issued to investors on Friday. They currently have a $21.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 18.64% from the stock’s previous close.

A number of other analysts also recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Abeona Therapeutics in a research report on Monday, September 18th. Royal Bank Of Canada began coverage on Abeona Therapeutics in a research report on Thursday, September 14th. They set an “outperform” rating and a $23.00 price objective for the company. Maxim Group set a $17.00 price objective on Abeona Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, August 29th. Zacks Investment Research downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Finally, BidaskClub downgraded Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $18.50.

Abeona Therapeutics (NASDAQ:ABEO) opened at 17.70 on Friday. The company’s market cap is $713.08 million. The firm’s 50-day moving average is $13.95 and its 200-day moving average is $8.24. Abeona Therapeutics has a 52-week low of $4.05 and a 52-week high of $18.90.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.07). Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. The company had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.21 million. On average, equities research analysts anticipate that Abeona Therapeutics will post ($0.68) EPS for the current year.

WARNING: “Abeona Therapeutics Inc. (ABEO) Stock Rating Reaffirmed by Cantor Fitzgerald” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/08/abeona-therapeutics-inc-abeo-stock-rating-reaffirmed-by-cantor-fitzgerald.html.

Several large investors have recently modified their holdings of ABEO. State Street Corp acquired a new stake in shares of Abeona Therapeutics during the 2nd quarter worth about $1,900,000. Northern Trust Corp increased its position in shares of Abeona Therapeutics by 406.3% during the 2nd quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock worth $1,649,000 after purchasing an additional 206,775 shares during the last quarter. Highbridge Capital Management LLC increased its position in shares of Abeona Therapeutics by 23.5% during the 1st quarter. Highbridge Capital Management LLC now owns 681,611 shares of the biopharmaceutical company’s stock worth $3,408,000 after purchasing an additional 129,811 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Abeona Therapeutics by 11.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock worth $6,922,000 after purchasing an additional 108,730 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Abeona Therapeutics by 869.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 116,000 shares of the biopharmaceutical company’s stock worth $580,000 after purchasing an additional 104,038 shares during the last quarter. 38.38% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Stock Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related stocks with our FREE daily email newsletter.